ATE323081T1 - N-formylhydroxylamin verbindungen als inhibitoren von pdf - Google Patents

N-formylhydroxylamin verbindungen als inhibitoren von pdf

Info

Publication number
ATE323081T1
ATE323081T1 AT02754681T AT02754681T ATE323081T1 AT E323081 T1 ATE323081 T1 AT E323081T1 AT 02754681 T AT02754681 T AT 02754681T AT 02754681 T AT02754681 T AT 02754681T AT E323081 T1 ATE323081 T1 AT E323081T1
Authority
AT
Austria
Prior art keywords
formylhydroxylamin
pdf
inhibitors
compounds
formylhydroxylamin compounds
Prior art date
Application number
AT02754681T
Other languages
English (en)
Inventor
Dinesh V Patel
Zhengyu Yuan
Rakesh K Jain
Alvarez Salvador Garcia
Jeffrey Jacobs
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Application granted granted Critical
Publication of ATE323081T1 publication Critical patent/ATE323081T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02754681T 2001-06-15 2002-06-14 N-formylhydroxylamin verbindungen als inhibitoren von pdf ATE323081T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29841901P 2001-06-15 2001-06-15
US36031302P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
ATE323081T1 true ATE323081T1 (de) 2006-04-15

Family

ID=26970649

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02754681T ATE323081T1 (de) 2001-06-15 2002-06-14 N-formylhydroxylamin verbindungen als inhibitoren von pdf

Country Status (30)

Country Link
US (1) US7148242B2 (de)
EP (1) EP1401828B1 (de)
JP (1) JP4361365B2 (de)
KR (2) KR20060014083A (de)
CN (1) CN1511152A (de)
AR (1) AR036053A1 (de)
AT (1) ATE323081T1 (de)
AU (1) AU2002321062B2 (de)
BR (1) BR0210377A (de)
CA (1) CA2448526A1 (de)
CO (1) CO5640131A2 (de)
CY (1) CY1105085T1 (de)
CZ (1) CZ20033388A3 (de)
DE (1) DE60210612T2 (de)
DK (1) DK1401828T3 (de)
ES (1) ES2262824T3 (de)
HU (1) HUP0400208A3 (de)
IL (1) IL158770A0 (de)
MX (1) MXPA03011628A (de)
MY (1) MY138619A (de)
NO (1) NO327420B1 (de)
NZ (1) NZ529489A (de)
PE (1) PE20030100A1 (de)
PL (1) PL364476A1 (de)
PT (1) PT1401828E (de)
RU (1) RU2325386C2 (de)
SI (1) SI1401828T1 (de)
SK (1) SK15242003A3 (de)
WO (1) WO2002102790A1 (de)
ZA (1) ZA200308379B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406893B1 (de) * 2001-06-15 2007-04-18 Vicuron Pharmaceuticals, Inc. Bicyclische pyrrolidinverbindungen
GB0208579D0 (en) * 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
ES2321504T3 (es) 2002-09-19 2009-06-08 Novartis Ag Proceso para la preparacion de productos intermedios.
AU2004216178B2 (en) * 2003-02-21 2008-07-03 Novartis Ag Chemical process for the preparation of intermediates to obtain N-formyl hydroxylamine compounds
TW200427458A (en) * 2003-04-02 2004-12-16 Novartis Ag Crystalline N-formyl hydroxylamine compounds
EP1641778A1 (de) * 2003-06-26 2006-04-05 Novartis AG Verfahren zur herstellung von zwischenprodukten für antibakterielle n-formyl hydroxylamine
KR100527624B1 (ko) * 2003-08-21 2005-11-22 한기종 질소에 포밀기를 갖는 아민유도체의 새로운 제조방법
EP1763348A1 (de) * 2004-06-30 2007-03-21 Novartis AG Verfahren zur erhöhung der suszeptibilität von peptiddeformylasehemmern mittels verwendung von effluxpumpenhemmern
EP1827449A4 (de) * 2004-11-17 2008-01-23 Smithkline Beecham Corp Verwendung von neuen antibakteriellen verbindungen
GT200600196A (es) * 2005-05-23 2007-01-15 Compuestos n-formil de hidroxilamina
US7705037B2 (en) 2005-06-07 2010-04-27 Novartis Ag 1-substituted pyrrolidin-2-ones and use thereof as peptide deformylase inhibitors
DE102005026231A1 (de) * 2005-06-07 2006-12-14 Origenis Ag Peptid-Deformylase (PDF) Inhibitoren 3
SG133452A1 (en) * 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
MX2008011128A (es) * 2006-03-03 2008-09-08 Novartis Ag Compuestos de n-formil-hidroxilamina.
CN101328155B (zh) * 2007-06-20 2010-11-03 上海医药工业研究院 噁唑烷衍生物及其制备方法和应用
CN101434570B (zh) * 2007-11-16 2011-02-02 上海医药工业研究院 吡咯烷衍生物及其制备方法和应用
CN101584694B (zh) * 2009-06-15 2011-01-12 华东师范大学 含2,5-二氢吡咯的肽脱甲酰基酶抑制剂及合成方法
EP2473502A1 (de) * 2009-09-04 2012-07-11 Novartis AG Heteroarylverbindungen als kinasehemmer
SG183192A1 (en) 2010-03-10 2012-09-27 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
JP5825086B2 (ja) 2011-12-19 2015-12-02 住友化学株式会社 α−置換−β−アミノ酸エステル誘導体不斉加水分解酵素
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3280795B1 (de) 2015-04-07 2021-03-24 Novartis AG Kombination von chimärer antigen rezeptor therapie und amino pyrimidin derivaten
US10738028B2 (en) * 2016-05-11 2020-08-11 Rudong Ruien Pharmaceutical Technology Co. Ltd Spiro three-membered ring, spiro five-membered ring peptide deformylase inhibitor and use thereof in antibacteria and anti-tumor

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226385A (en) * 1963-10-11 1965-12-28 American Cyanamid Co Substituted 3-(alpha-acyloxy-lower alkyl)-4,7-indoloquinones
US4052511A (en) 1976-02-13 1977-10-04 E. R. Squibb & Sons, Inc. Carboxyacylproline derivatives
US4311705A (en) 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
US4303662A (en) 1980-11-24 1981-12-01 E. R. Squibb & Sons, Inc. Carboxyacyl, mercapto and acylmercapto derivatives of heterobicyclo compounds
US4321383A (en) 1980-11-24 1982-03-23 E. R. Squibb & Sons, Inc. Heterobicyclo intermediates
JPS6188884A (ja) 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼｂ阻害物質およびその製法
AU580855B2 (en) * 1985-03-29 1989-02-02 Shionogi & Co., Ltd. Alkeneamidocephalosporin esters
US4599361A (en) 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
US5128346A (en) 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
EP0334244A3 (de) 1988-03-25 1991-05-29 The Procter & Gamble Company Peptide-Antagonisten von Bradykinin
GB8827308D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) 1989-08-24 1989-10-04 British Bio Technology Compounds
GB8921326D0 (en) 1989-09-21 1989-11-08 Beecham Group Plc Novel treatment
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
ATE120182T1 (de) 1990-12-03 1995-04-15 Celltech Ltd Peptidylderivate.
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
IT1245712B (it) 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
AU2228292A (en) 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
US5256657A (en) 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
KR100255203B1 (ko) 1991-11-08 2000-05-01 가와무라 요시부미 콜라게나제 저해제
EP0634998B1 (de) 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
GB9211707D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211706D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
AU672888B2 (en) 1993-03-18 1996-10-17 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
JPH08500124A (ja) 1993-04-27 1996-01-09 セルテック セラピューティックス リミテッド メタロプロテイナーゼインヒビターとしてのペプチジル誘導体
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
GB9411598D0 (en) 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
GB9502858D0 (en) 1995-02-14 1995-04-05 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
GB9504084D0 (en) 1995-03-01 1995-04-19 British Biotech Pharm Synthesis of carboxylic and hydroxamic acid derivatives
FR2733750B1 (fr) 1995-05-03 1997-06-13 Synthelabo Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique
CA2246753C (en) 1996-02-23 2005-05-10 Eli Lilly And Company Non-peptidyl vasopressin v1a antagonists
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
GB9613547D0 (en) 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
CA2265671A1 (en) 1997-07-10 1999-01-21 Daniela Jabes Matrix metalloproteinase inhibitors
EP1052984B1 (de) 1998-02-07 2004-05-12 Vernalis (Oxford) Ltd Antibakterielle mittel

Also Published As

Publication number Publication date
PE20030100A1 (es) 2003-03-28
HUP0400208A3 (en) 2008-10-28
DE60210612D1 (de) 2006-05-24
ZA200308379B (en) 2004-05-21
CA2448526A1 (en) 2002-12-27
NO327420B1 (no) 2009-06-29
AR036053A1 (es) 2004-08-04
NO20035571L (no) 2004-02-16
PL364476A1 (en) 2004-12-13
SI1401828T1 (sl) 2006-10-31
EP1401828A1 (de) 2004-03-31
CZ20033388A3 (en) 2004-03-17
KR20040010721A (ko) 2004-01-31
AU2002321062B2 (en) 2006-02-02
JP2005502606A (ja) 2005-01-27
DE60210612T2 (de) 2006-09-21
CY1105085T1 (el) 2009-11-04
WO2002102790A1 (en) 2002-12-27
CN1511152A (zh) 2004-07-07
JP4361365B2 (ja) 2009-11-11
HUP0400208A2 (hu) 2004-06-28
SK15242003A3 (sk) 2004-07-07
US20030045479A1 (en) 2003-03-06
MY138619A (en) 2009-07-31
MXPA03011628A (es) 2005-03-07
IL158770A0 (en) 2004-05-12
NO20035571D0 (no) 2003-12-12
PT1401828E (pt) 2006-08-31
US7148242B2 (en) 2006-12-12
CO5640131A2 (es) 2006-05-31
ES2262824T3 (es) 2006-12-01
HK1064370A1 (en) 2005-01-28
RU2003137565A (ru) 2005-05-27
EP1401828B1 (de) 2006-04-12
BR0210377A (pt) 2004-08-10
DK1401828T3 (da) 2006-07-31
NZ529489A (en) 2005-10-28
RU2325386C2 (ru) 2008-05-27
KR20060014083A (ko) 2006-02-14
KR100589544B1 (ko) 2006-06-15

Similar Documents

Publication Publication Date Title
ATE323081T1 (de) N-formylhydroxylamin verbindungen als inhibitoren von pdf
ATE294805T1 (de) Triazoloverbindungen als mmp-inhibitoren
ATE370938T1 (de) Pro-pharmakon von cox-2-inhibitoren
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE60321324D1 (de) Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
DE60221875D1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE60305061D1 (de) 2-pyridonderivate als inhibitoren von neutrophiler elastase
DE60219682D1 (de) Harnstofe von 2-aminobenzothiazolen als adenosin-modulatoren
ATE493406T1 (de) Hydantoinderivate als mmp-inhibitoren
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
DE602004010151D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DK1448523T3 (da) Heterocycliske forbindelser samt metoder til anvendelse deraf
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
ATE323072T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
DE60112276D1 (de) Elektrophoretische trennung von verbindungen
DE602004013990D1 (de) Ernen von spänen
DE50212455D1 (de) Verwendung von Dimerdiolen
DE60324208D1 (de) Biarylsulfonamide als mmp-inhibitoren
NO20033679D0 (no) Nye pyrimidinforbindelser
DE60136178D1 (de) Verwendung von ketonen als vorstufen von aktiven verbindungen
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1401828

Country of ref document: EP

REN Ceased due to non-payment of the annual fee